Individual financial statement for Q4 of 2017
Insider trading disclosure of December, 29 2017 received by Rositsa Doneva
Insider trading disclosure of December, 29 2017 received by Ognian Donev
Insider trading disclosure of December, 22 2017 received by Ognian Donev
Insider trading disclosure of December, 21 2017 received by Ognian Donev
Notification for received approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD
Sopharma AD notifies that on 20 December 2018 Sopharma AD received an approval from the FSC of the contract for transformation through merger of Unipharm AD in Sopharma AD and reports of the boards of directors and the independent evaluators. The fair price of the participants in the transformation is based on widely accepted evaluation methods. Based on the fair price the participants in the transformation reached a ratio of exchange of 0. 891512, meaning that one share of Unipharm AD will be exchanged for 0.
Notification for acquisition of own shares
Sopharma AD hereby informs that on 20 December 2017 the Company bought 10 934 own shares representing 0.0081% of the share capital of the Company, at a total value of 46 697.52 BGN on the Bulgarian Stock Exchange, the average price per share was 4.27 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
Insider trading disclosure of December, 20 2017 received by Elpharma AD
Insider trading disclosure of December, 20 2017 received by Ognian Donev
Strony
- « pierwsza
- ‹ poprzednia
- …
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- …
- następna ›
- ostatnia »